Two months into the COVID-19 outbreak, China is gradually stepping out of a nationwide lockdown, back to the hustle and bustle of restaurants and steaming chimneys of factories, with a steep drop in the volume of patients in the majority of hospitals. This dramatic turnaround and front-line battle made by the public health workers has demonstrated that China’s healthcare system is more mature and resilient than in the 2003 SARS outbreak.
Technological advancement has supported the optimal diagnosis and treatment of COVID-19 patients, as well as day-to-day public health needs. This has ranged from government-led COVID-19 clinical trials to the inclusion of ‘Internet+’ medical service in health insurance.
We hope these reports can shed some light on the questions that have arisen regarding the domestic economy, healthcare industry and specifically, the medical devices sector in China.
Part 2 report highlights include:
Coronavirus: Global trends and impact on China’s healthcare industry in Q1
- Global outbreak tracking, and potential risks and challenges
- Impact on the value of healthcare in China, and expected recovery
- Forecasting the speed of recovery for outpatient, inpatient and surgery volumes in China for 2020
- Forecasting the impact on the medical devices & diagnostics market in 2020, and the market’s subsequent development during China’s 14th Five Year Plan
Hospital volumes and consumables tracking (Jan. and Feb. 2020): An Ipsos study sampled from 40 hospitals in major provinces across China
- Extent of the impact on hospital outpatient, inpatient and surgery volumes
- Year-on-year comparison of surgery volume in main departments
- Usage change in the volume of selected low- and high-value consumables
Ongoing reports will be added here, as they are released:
|Part 2||April 21|
|Part 1||March 25|